ArticlesEffect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial
Introduction
Interventions that slow HIV-1 disease progression could postpone the need for antiretroviral therapy and extend life expectancy of HIV-infected people, thus safe, effective, and low cost approaches to delay HIV disease progression are urgently needed. Despite the success achieved in scaling up antiretroviral therapy, most people infected with HIV-1 in low-income and middle-income countries are not yet taking antiretroviral therapy, because either they do not meet current criteria, or they do not have access. With many programmes facing funding constraints, cost-effective measures to delay initiation of antiretroviral therapy are needed.
Herpes simplex virus type 2 (HSV-2) has been shown to upregulate HIV-1 replication at the cellular level and to increase HIV-1 viral load.1 HSV-2 is the commonest cause of genital ulcer disease; seroprevalence of HSV-2 in HIV-1 infected individuals ranges from 70% to more than 90%.2, 3 Genital ulcer disease is prevalent in HIV-infected individuals and increases the risk of HIV transmission to uninfected partners.4 Reactivation of HSV-2 is common in people with HIV-1 and plasma and genital HIV-1 concentrations increase during reactivation.3, 5, 6, 7 HIV-1 viral load in plasma is the key determinant of HIV progression and transmission.8, 9 A meta-analysis of seven randomised trials of daily herpes suppressive therapy with aciclovir or valaciclovir for 8–12 weeks showed a 0·33 log10 copies per mL reduction in median plasma HIV-1 RNA concentration and one randomised controlled trial has shown a modest (16%) reduced risk of HIV disease progression in patients taking daily aciclovir.10, 11 We did a trial of aciclovir 400 mg twice daily to assess the effect on HIV disease progression in individuals in Uganda infected with HIV and HSV-2 who were not yet eligible for antiretroviral therapy.
Section snippets
Participants and study design
Eligible HIV-1, HSV-2 co-infected individuals aged 18 years and older from Rakai Health Sciences Program and affiliated HIV care programmes in the area were recruited between May 2007, and November 2008. Inclusion criteria were seropositivity for HIV-1 and HSV-2, and a CD4 cell count between 300 and 400 cells per μL. We excluded individuals with AIDS-defining illnesses, and individuals receiving antiretroviral therapy. All participants provided written informed consent. The study was approved
Results
Figure 1 shows the trial profile. 1404 potential participants were assessed for HSV-2, of whom 1236 (88%) were HSV-2 seropositive, 989 (80%) of whom were screened sequentially for enrolment up to the time of full enrolment. The major screening criterion that precluded enrolment was CD4 cell count outside the eligible range. Of the 504 participants deemed ineligible because of CD4 cell count, the high (n=290) and low (n=214) median CD4 cell counts per μL were 475 (IQR 434–549) and 248 (219–276)
Discussion
Aciclovir 400 mg twice daily for suppression of HSV-2 in HIV-1 co-infected individuals reduced the risk of HIV-1 disease progression by 25%. Ours is the second study with a disease progression endpoint (panel) and this result is similar although larger than the 16% reduction in the Partners in Prevention HSV/HIV Transmission study.10 This difference might be because of differences in enrolment criteria; CD4 cell counts between 300 and 400 cells per μL in this study, whereas the Partners study
References (29)
- et al.
Herpes simplex virus infection induces replication of human immunodeficiency virus type 1
Virology
(2000) - et al.
Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial
Lancet
(2010) - et al.
Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial
Lancet
(2008) - et al.
A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial
Lancet
(2006) - et al.
The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course?
Virology
(1994) - et al.
Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues
Cell Host Microbe
(2008) - et al.
Mechanisms associated with HIV-1 resistance to acyclovir by the V75I mutation in reverse transcriptase
J Biol Chem
(2009) - et al.
Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials
Lancet
(2012) - et al.
An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection
Bull World Health Organ
(2008) - et al.
Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention
J Infect Dis
(2000)
Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda
J Infect Dis
Association between cervical shedding of herpes simplex virus and HIV-1
AIDS
The impact of active herpes simplex virus infection on human immunodeficiency virus load
J Infect Dis
Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men
JAMA
Cited by (35)
Herpes Simplex Virus
2014, Mandell, Douglas, and Bennett's Principles and Practice of Infectious DiseasesA pilot study examining the safety and tolerability of valacyclovir in veterans with hepatitis C virus/herpes simplex virus type 2 coinfection
2014, American Journal of the Medical SciencesCitation Excerpt :These previous investigations demonstrated that short courses of HSV-2 suppression could reduce plasma HIV viral load by approximate 0.25 to 0.50 log10 copies/mL.8,9 Studies examining longer durations of HSV-2 suppression in HIV/HSV-2-coinfected persons found these inexpensive and well-tolerated medications were associated with reduced risk for HIV disease progression.10,11,13 The mechanism behind these observations remains a subject of debate.
The Effect of Antiretroviral Therapy Initiation on the Vaginal Microbiome in HIV-Infected Women
2019, Open Forum Infectious DiseasesEffect of valaciclovir on CD4 count decline in untreated HIV: An international randomized controlled trial
2019, Journal of Antimicrobial ChemotherapySchistosomiasis was not associated with higher HIV-1 plasma or genital set point viral loads among HIV seroconverters from four cohort studies
2019, PLoS Neglected Tropical DiseasesHiv-1-infected cell-derived exosomes promote the growth and progression of cervical cancer
2019, International Journal of Biological Sciences